

Table 14-6.05
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		P-value [2]
	Shift [1]	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
CHEMISTRY							

ALANINE AMINOTRANSFERASE	n 82	2	79	1	80	0	0.828
	Normal 80 (98%)	0	78 (99%)	0	78 (98%)	0	
	High 2 (2%)	2 (100%)	1 (1%)	1 (100%)	2 (3%)	0	
ALBUMIN	n 84	0	80	0	80	0	
	Normal 84 (100%)	0	80 (100%)	0	80 (100%)	0	
ALKALINE PHOSPHATASE	n 82	2	79	0	79	1	0.611
	Normal 81 (99%)	0	78 (99%)	0	79 (100%)	0	
	High 1 (1%)	2 (100%)	1 (1%)	0	0	1 (100%)	
ASPARTATE AMINOTRANSFERASE	n 82	2	79	1	80	0	0.770
	Normal 79 (96%)	1 (50%)	77 (97%)	1 (100%)	78 (98%)	0	
	High 3 (4%)	1 (50%)	2 (3%)	0	2 (3%)	0	
BILIRUBIN	n 84	0	80	0	79	1	0.353
	Normal 83 (99%)	0	80 (100%)	0	77 (97%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		P- value [2]
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
		High	1 (1%)	0	0	0	2 (3%)	1 (100%)
CALCIUM	n	84	0	80	0	80	0	0.811
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
CHLORIDE	n	84	0	80	0	79	0	0
	Normal	84 (100%)	0	80 (100%)	0	79 (100%)	0	
CHOLESTEROL	n	84	0	80	0	80	0	0
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
CREATINE KINASE	n	84	0	79	1	77	3	0.898
	Normal	77 (92%)	0	74 (94%)	1 (100%)	72 (94%)	1 (33%)	
	High	7 (8%)	0	5 (6%)	0	5 (6%)	2 (67%)	
CREATININE	n	84	0	80	0	80	0	0
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
GAMMA GLUTAMYL TRANSFERASE	n	82	2	78	2	78	2	0.898
	Normal	80 (98%)	0	75 (96%)	1 (50%)	76 (97%)	1 (50%)	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		P- value [2]	
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline		
		High	2 (2%)	2 (100%)	3 (4%)	1 (50%)	2 (3%)		
GLUCOSE	n	83		1	80	0	80	0	0.354
	Normal	83 (100%)		1 (100%)	79 (99%)	0	78 (98%)	0	
	High	0		0	1 (1%)	0	2 (3%)	0	
PHOSPHATE	n	84		0	79	0	80	0	
	Normal	84 (100%)		0	79 (100%)	0	80 (100%)	0	
POTASSIUM	n	84		0	79	0	79	0	
	Normal	84 (100%)		0	79 (100%)	0	79 (100%)	0	
PROTEIN	n	84		0	80	0	80	0	
	Normal	84 (100%)		0	80 (100%)	0	80 (100%)	0	
SODIUM	n	84		0	80	0	79	0	
	Normal	84 (100%)		0	80 (100%)	0	79 (100%)	0	
URATE	n	84		0	80	0	80	0	
	Normal	84 (100%)		0	80 (100%)	0	80 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		P- value [2]	
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline		
UREA NITROGEN	n	84	0	78	2	80	0	0.363	
	Normal	84 (100%)	0	78 (100%)	2 (100%)	79 (99%)	0		
	High	0	0	0	0	1 (1%)	0		
<hr/>									
HEMATOLOGY									
BASOPHILS	n	83	0	79	0	78	0	0.044	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0		
EOSINOPHILS	n	83	0	78	1	78	0	0.044	
	Normal	83 (100%)	0	73 (94%)	1 (100%)	72 (92%)	0		
	High	0	0	5 (6%)	0	6 (8%)	0		
ERY. MEAN CORPUSCULAR HBn CONCENTRATION		82	0	78	0	77	0		
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0		
ERY. MEAN CORPUSCULAR HEMOGLOBIN	n	83	0	79	0	78	0		
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0		

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		P- value [2]
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
ERY. MEAN CORPUSCULAR VOLUME	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
ERYTHROCYTES	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
HEMATOCRIT	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
HEMOGLOBIN	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
LEUKOCYTES	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
LYMPHOCYTES	n	83	0	79	0	78	0	0.388
	Normal	82 (99%)	0	79 (100%)	0	78 (100%)	0	
	High	1 (1%)	0	0	0	0	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		P- value [2]
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
MONOCYTES	n	83	0	79	0	78	0	0.150
	Normal	81 (98%)	0	79 (100%)	0	78 (100%)	0	
	Low	2 (2%)	0	0	0	0	0	
PLATELET	n	83	0	77	0	78	0	
	Normal	83 (100%)	0	77 (100%)	0	78 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006